Search

Displaying results 6631 - 6640 of 10000 in total
  1. Pathway

    Cardiolipin Biosynthesis CL(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(4Z,7Z,10Z,13Z,16Z)/20:5(5Z,8Z,11Z,14Z,17Z))

    smpdb.ca/view/SMP0215879
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  2. Pathway

    Cardiolipin Biosynthesis CL(18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))

    smpdb.ca/view/SMP0215893
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  3. Pathway

    Cardiolipin Biosynthesis CL(18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))

    smpdb.ca/view/SMP0216214
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  4. Pathway

    Cardiolipin Biosynthesis CL(20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))

    smpdb.ca/view/SMP0236729
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  5. Pathway

    Cardiolipin Biosynthesis CL(20:5(5Z,8Z,11Z,14Z,17Z)/18:1(9Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z))

    smpdb.ca/view/SMP0241216
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  6. Pathway

    Cardiolipin Biosynthesis CL(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/18:1(9Z)/20:5(5Z,8Z,11Z,14Z,17Z))

    smpdb.ca/view/SMP0255047
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  7. Pathway

    Cardiolipin Biosynthesis CL(20:5(5Z,8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)/20:5(5Z,8Z,11Z,14Z,17Z)/16:1(9Z))

    smpdb.ca/view/SMP0255117
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  8. Pathway

    Phosphatidylethanolamine Biosynthesis PE(15:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

    smpdb.ca/view/SMP0127155
    Metabolic

    Phosphatidylethanolamines (PE) are a class of phospholipids that incorporate a phosphoric acid headgroup into a diacylglycerol backbone. They are the second most abundant phospholipid in eukaryotic cell membranes, and contrary to phospha...

    Drugs: Choline · Serine · ATP · Cytidine-5'-Triphosphate · Ethanolamine · Pyrophosphoric acid
  9. Drug

    Orciprenaline

    go.drugbank.com/drugs/DB00816
    Approved

    A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]

    Categories: Adrenergic beta-2 Receptor Agonists, Selective Beta 2-adrenergic AgonistsProducts: Ratio-orciprenaline Syrup 2mg/ml, Tanta Orciprenaline Syrup - Syr 2mg/ml
  10. Drug

    Patisiran

    go.drugbank.com/drugs/DB14582
    Approved

    It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … Patisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220].

    Categories: Compounds used in a research, industrial, or household setting